BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3437623)

  • 1. A study on the correlation between estrogen receptor, progesterone receptor and tamoxifen binding sites in human breast cancer tissues.
    Imanaka Y; Tsuboi S; Kohno N; Saitoh Y
    Jpn J Surg; 1987 Nov; 17(6):487-92. PubMed ID: 3437623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
    J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
    Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
    Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
    Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a displacement assay with tamoxifen as prognostic indicator in breast-cancer patients with estrogen-receptor-positive tumors.
    Levin E; Actis AM; Caruso S; Gass H; Romero R; Qualeta N; Levin RW
    Int J Cancer; 1997 Nov; 73(4):486-91. PubMed ID: 9389560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene.
    Valavaara R; Tuominen J; Johansson R
    Cancer; 1990 Dec; 66(11):2264-9. PubMed ID: 2147123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
    Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG
    Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.
    Fernö M; Stål O; Baldetorp B; Hatschek T; Källström AC; Malmström P; Nordenskjöld B; Rydën S
    Breast Cancer Res Treat; 2000 Jan; 59(1):69-76. PubMed ID: 10752681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL;
    J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro.
    Paulsen GH; Strickert T; Marthinsen AB; Lundgren S
    Acta Oncol; 1996; 35(8):1011-9. PubMed ID: 9023387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
    Bonomi P; Gale M; Von Roenn J; Anderson K; Johnson P; Wolter J; Economou S
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.
    Foekens JA; Portengen H; van Putten WL; Peters HA; Krijnen HL; Alexieva-Figusch J; Klijn JG
    Cancer Res; 1989 Nov; 49(21):5823-8. PubMed ID: 2676151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer.
    Waseda N; Kato Y; Imura H; Kurata M
    Cancer Res; 1981 May; 41(5):1984-8. PubMed ID: 7214366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
    J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.
    Encarnación CA; Ciocca DR; McGuire WL; Clark GM; Fuqua SA; Osborne CK
    Breast Cancer Res Treat; 1993; 26(3):237-46. PubMed ID: 8251648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological quantitation of nuclear receptors in human breast cancer: relation to cytosolic estrogen and progesterone receptors.
    Thorpe SM
    Cancer Res; 1987 Apr; 47(7):1830-5. PubMed ID: 3545455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer.
    Hupperets PS; Volovics L; Schouten LJ; Jager JJ; Schouten HC; Hillen HF; Blijham GH
    Am J Clin Oncol; 1997 Dec; 20(6):546-51. PubMed ID: 9391537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.
    Paradiso A; Tommasi S; Mangia A; Lorusso V; Simone G; De Lena M
    Cancer Res; 1990 May; 50(10):2958-62. PubMed ID: 2334898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.